CA
PLX icon

Clearstead Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Clearstead Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-500
Closed -$1K – 826
2020
Q1 		$1K Buy
+500
New +$1.65K ﹤0.01% 751

Other funds holding PLX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Clearstead Advisors's PLX Position: Q2 2020 in Review

Clearstead Advisors sold out of Protalix BioTherapeutics (PLX) in Q2 2020, closing a stake of 500 shares — an estimated $1K sold.

Clearstead Advisors first reported a position in PLX in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 28 funds tracked by Wall St. Rank hold PLX as of Q2 2020.

  • Clearstead Advisors reported no remaining Protalix BioTherapeutics position as of Q2 2020 after selling out during the quarter.
  • Clearstead Advisors sold 500 Protalix BioTherapeutics shares in Q2 2020, an estimated $1K.
  • Clearstead Advisors first reported a position in Protalix BioTherapeutics in Q1 2020 and held it in 1 quarter.
  • Clearstead Advisors's Protalix BioTherapeutics position peaked at $1K in Q1 2020.
  • 28 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2020.

Based on Clearstead Advisors's 13F filing for Q2 2020, filed 11 Aug 2020.